论文部分内容阅读
液氮局部冷冻治疗肝癌１５２例，其中原发性肝癌（ＰＬＣ）１４５例，转移性肝癌（ＳＬＣ）．例，１４５例ＰＬＣ中，Ⅰ期４６例（３１．７％），Ⅱ期９１例（６２．８％），Ⅲ期８例（５．５％）。全组无手术死亡。１４５例ＰＬＣ患者冷冻后１、３、５年生存率分别为６９．２％、４９．２％、３４．８％；其中ＰＬＣ≤５ｃｍ４１例患者则分别为９１．０％、７６．５％、６４．２％。７例ＳＬＣ患者冷冻后平均生存２２．３个月（４～１１２个月）．文中提示，冷冻治疗肝癌是一种安全可行的局部治疗方法。冷冻治疗小肝癌，可达根治目的；对较大肝癌，冷冻可作为综合治疗的一个手段。
There were 152 cases of liver cancer treated with liquid nitrogen local cryotherapy, including 145 cases of primary liver cancer (PLC) and metastatic liver cancer (SLC). For example, in 145 PLCs, 46 patients (31.7%) were in phase I, 91 (62.8%) were in phase II, and 8 (5.5%) were in phase III. There was no operative death in the entire group. The 1-, 3-, and 5-year survival rates of 145 PLC patients after cryopreservation were 69.2%, 49.2%, and 34.8%, respectively; of the 41 patients with PLC ≤ 5cm, the survival rates were 91.0% and 76.5%, respectively. 64.2%. Seven patients with SLC survived an average of 22.3 months after freezing (4 to 112 months). The article suggests that cryotherapy of liver cancer is a safe and feasible method of local treatment. Cryotherapy for small hepatocellular carcinoma can achieve the goal of radical cure; for larger liver cancer, freezing can be used as a means of comprehensive treatment.